Corline Biomedical AB (CLBIO) - Cash Flow Conversion Efficiency

Latest as of June 2026: 0.001x

Based on the latest financial reports, Corline Biomedical AB (CLBIO) has a cash flow conversion efficiency ratio of 0.001x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr122.00K ≈ $13.13K USD) by net assets (Skr99.00 Million ≈ $10.65 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Corline Biomedical AB market cap and net worth for the company's overall valuation and market capitalisation.

Corline Biomedical AB - Cash Flow Conversion Efficiency Trend (2013–2025)

This chart illustrates how Corline Biomedical AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Corline Biomedical AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Corline Biomedical AB ranked by their cash flow conversion efficiency. Explore Corline Biomedical AB cash flow quality index to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
WT Financial Group Ltd AU:WTL	0.125x
Novacyt PA:ALNOV	-0.141x
Zaklady Przemyslu Cukierniczego Otmuchow S.A. WAR:OTM	0.034x
IHQ Inc KO:003560	0.072x
Chih Lien Industrial Co Ltd TW:2024	0.020x
Staatl. Mineralbrunnen AG MU:SLB	N/A
Epitomee Medical Ltd TA:EPIT	-0.416x
Edesa Biotech Inc NASDAQ:EDSA	-0.346x

Annual Cash Flow Conversion Efficiency for Corline Biomedical AB (2013–2025)

The table below shows the annual cash flow conversion efficiency of Corline Biomedical AB from 2013 to 2025. View Corline Biomedical AB (CLBIO) share price today for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr93.76 Million ≈ $10.09 Million	Skr-17.69 Million ≈ $-1.90 Million	-0.189x	-89.81%
2024-12-31	Skr86.91 Million ≈ $9.35 Million	Skr-8.64 Million ≈ $-929.69K	-0.099x	-1146.88%
2023-12-31	Skr93.32 Million ≈ $10.04 Million	Skr886.00K ≈ $95.35K	0.009x	+113.92%
2022-12-31	Skr94.59 Million ≈ $10.18 Million	Skr-6.45 Million ≈ $-694.34K	-0.068x	-30.12%
2021-12-31	Skr92.23 Million ≈ $9.93 Million	Skr-4.83 Million ≈ $-520.32K	-0.052x	+46.16%
2020-12-31	Skr52.03 Million ≈ $5.60 Million	Skr-5.07 Million ≈ $-545.18K	-0.097x	+58.27%
2019-12-31	Skr59.32 Million ≈ $6.38 Million	Skr-13.84 Million ≈ $-1.49 Million	-0.233x	-212.44%
2018-12-31	Skr54.96 Million ≈ $5.91 Million	Skr-4.10 Million ≈ $-441.66K	-0.075x	+31.11%
2017-12-31	Skr45.93 Million ≈ $4.94 Million	Skr-4.98 Million ≈ $-535.71K	-0.108x	+41.76%
2016-12-31	Skr38.75 Million ≈ $4.17 Million	Skr-7.21 Million ≈ $-776.02K	-0.186x	+6.53%
2015-12-31	Skr21.25 Million ≈ $2.29 Million	Skr-4.23 Million ≈ $-455.34K	-0.199x	+52.91%
2014-12-31	Skr5.48 Million ≈ $590.25K	Skr-2.32 Million ≈ $-249.55K	-0.423x	-22.53%
2013-12-31	Skr8.00 Million ≈ $860.60K	Skr-2.76 Million ≈ $-296.95K	-0.345x	--

About Corline Biomedical AB

ST:CLBIO Sweden Biotechnology

Market Cap

$39.94 Million

Skr371.09 Million SEK

Market Cap Rank

#22830 Global

#428 in Sweden

Share Price

Skr14.20

Change (1 day)

-3.73%

52-Week Range

Skr14.20 - Skr21.20

All Time High

Skr28.20